Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

Need2immune

Financiado

Cerrado

Personalized liposomal cancer vaccines within days by rapid formulation screenin...

Personalized liposomal cancer vaccines within days by rapid formulation screening Cancer immunotherapy, defined as the ability to mobilise the host’s own immune system to kill cancer, has recently within the last 5 years, taken a central role within mainstream oncology. This period has seen the field rapidly ac... ver más

31/08/2021

TECOD

163K€

Presupuesto del proyecto: 163K€

Líder del proyecto

TECODEVELOPMENT GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-08-31

MSCA-IF-2018: Individual Fellowships Objective:The goal of the Individual Fellowships is to enhance the creative and innovative potential...

I+D

Cerrada hace 6 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TECOD

162.81K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 29 meses Fecha Inicio: 2019-03-29
Fecha Fin: 2021-08-31

Líder del proyecto

TECODEVELOPMENT GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 163K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer immunotherapy, defined as the ability to mobilise the host’s own immune system to kill cancer, has recently within the last 5 years, taken a central role within mainstream oncology. This period has seen the field rapidly accelerate towards unprecedented clinical responses in patients, and the development of novel classes of immunotherapeutic drugs. One approach has been to design more personalised immunotherapies along with new methods in delivering the therapeutic cargo. It is anticipated that this will play a defining role for cancer immunotherapy in terms of how to better achieve sustained remissions or complete eradication. One of the challenges in the future will be to understand how to administer these molecules since the current approach of systemic administration harbours the risk of causing serious toxicity and/or autoimmunity. This could drastically lower the serum levels of immune reagents needed with a decrease in adverse effects and lower risk of autoimmune reactions, without losing systemic efficacy. Currently, cancer immunotherapies are injected into the bloodstream but systemic injections have many drawbacks. It could be more effective therefore to inject this kind of therapy locally and directly to target tumour cells. This proposal will be to implement a more direct approach, where the immunotherapy's effects could be more easily controlled, with also the possibility for lower doses to be administered. Recently, microneedles have been attracting attention as new drug delivery tools. The microneedle has already been shown to be a highly effective intradermal and transdermal vaccine delivery method due to its mechanism of action, painlessness and ease of use. The goal is therefore to use microneedles to deliver localised doses of combination immunotherapies, e.g. vaccine with checkpoint modulators, in nanoparticles, as the focus of a novel approach to developing new strategies for the trackable delivery of onco-immunotherapeutic agents.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores